The recently published WHO 2022 classification of AML is based on patient history (previous chemotherapy or hematological disease), karyotype, and molecular genetic analyses, including the molecular abnormalities ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 referred to as associated with myelodysplastic syndrome associated [41]. This evidence concerns the gene STAG2 and myelodysplastic syndrome.